Owlstone Medical Ltd.Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?
Tag Archive for: UK
Adobe stock Photos - hkama Overnight, US President Donald Trump broke previous tariff agreements with the United Kingdom and the EU, announcing that from 1 October, patented medicines not produced in the US will be subject to a 100% tariff.
adobe stock photo - TokoThe Association of the British Pharmaceutical Industry (ABPI) has warned that the UK could miss its target of becoming the number one in European life sciences by 2030.
Cyril MarcilhacyThe British Food Standards Agency (FSA) has formally accepted an application by French start-up Gourmey SAS for regulatory approval of its cultivated foie gras, a product developed using cellular agriculture techniques. The submission was initially lodged on 26 July 2024 and was made in parallel across five jurisdictions: the European Union, United States, Singapore, Switzerland, and the United Kingdom.
Nucleara LtdCambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
Sphere FluidicsDale Levitzke has been appointed as CEO of Sphere Fluidics. He follows CEO and co-founder Dr Frank F. Craig, who announced his retirement after 14 years leading the company.
In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.
British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
UK-based CRO Cresset has expanded its senior leadership team with the appointment of Nick Foster as Vice President of their Discovery CRO business.